

MEPNN Supplier Scouting Opportunity Synopsis

Section 1: General Information

Scouting Number	2026-590
Item to be Scouted	Pharmaceutical Manufacturers
Days to be scouted	30
Response Due By	11/13/2026
Description	C3 Pharmaceuticals is developing Idrasil™, a prototype-ready, titratable, anhydrous cannabinoid pharmaceutical tablet intended to support non-opioid pain management, sleep support, recovery, and quality of life improvement.

Section 2: Technical Information

Type of supplier being sought	Manufacturer
Reason	2nd Supply Efforts, and future federal contracting opportunities. Manufacturers with experience supporting government, Department of Defense, VA, and clinical research programs are encouraged to respond.
Describe the manufacturing processes (elaborate to provide as much detail as possible)	Seeking manufacturers experienced in pharmaceutical tablet formulation and production, including cannabinoid-based active ingredient handling, blending, granulation, compression, coating, quality assurance, stability testing, and commercial packaging. Preference for facilities operating under current Good Manufacturing Practices (cGMP), FDA-compliant quality systems, clinical trial material production, and scalable commercial manufacturing capabilities.
Provide dimensions / size / tolerances / performance specifications for the item	Idrasil™ is a prototype-ready, anhydrous, titratable cannabinoid pharmaceutical tablet being developed by C3 Pharmaceuticals for non-opioid pain management, recovery support, sleep enhancement, and quality-of-life improvement. The product is intended to support moderate pain management (pain scale 4-7) while reducing opioid exposure and supporting opioid recovery programs. C3 Pharmaceuticals is seeking platform-based OEMs to support production of Idrasil™ tablets in 12.5 Mg., 25Mg., 100Mg. sizes. OEMs should provide evidence of manufacturing capabilities for anhydrous development, design, clinical data stability, and packaging integrated to support food-grade cannabinoid production management, sleep support, and recovery health care applications. California
List required materials needed to make the product, including materials of product components	Cannabinoid active pharmaceutical ingredients (API), pharmaceutical excipients, tablet binders, fillers, flow agents, coating materials, moisture-control packaging components, blister packaging, bottles, desiccant systems, labeling materials, and quality control testing materials. Manufacturer should have experience sourcing pharmaceutical-grade ingredients and maintaining GMP supply chain requirements. (Recipe protected by Intellectual property.
Are there applicable certification requirements?	No
Are there applicable regulations?	No
Are there any other standards, requirements, etc.?	No
Additional Technical Comments	C3 Pharmaceuticals seeks U.S. manufacturing partners capable of supporting prototype-to-commercial development of Idrasil™, a titratable cannabinoid tablet designed as a non-opioid alternative for pain management and recovery support. Interest includes military healthcare applications, veteran healthcare programs, opioid reduction initiatives, and future federal contracting opportunities. Manufacturers with experience in pharmaceutical scale-up, clinical trials, government contracting, and secure supply chains are strongly preferred.

Section 4: Business Information

Estimated potential business volume	Initial prototype and pilot production runs anticipated. Commercial demand projections include military, veteran, rehabilitation, and civilian healthcare markets with scalable production requirements ranging from clinical batches to large-scale commercial manufacturing.
Estimated target price / unit cost information (if unavailable explain)	Seeking manufacturer input and quotations based upon pilot production, clinical manufacturing, and commercial scale production volumes. Cost structure to be determined following formulation review and manufacturing assessment.
When is it needed by?	Immediate. Manufacturer identification requested within 30 days to support product development, regulatory planning, military commercialization opportunities, and future clinical manufacturing activities.
Describe packaging requirements	Seeking manufacturer capabilities for pharmaceutical-grade packaging, including moisture-resistant blister packs, HDPE bottles with desiccant systems, tamper-evident and child-resistant packaging, serialization, labeling, and military deployment-ready packaging options. Anhydrous tablet formulation requires moisture-control protection to maintain product stability and shelf life. Packaging should support clinical trial materials, pilot production, and future commercial distribution.
Where will this item be shipped?	Initial shipments to C3 Pharmaceuticals development and testing facilities in California. Future distribution anticipated to military treatment facilities, veteran healthcare systems, clinical trial sites, pharmaceutical distributors, and commercial healthcare channels throughout the United States.

Additional Comments

Is there other information you would like to include?	C3 Pharmaceuticals is developing Idrasil™, a prototype-ready, titratable, anhydrous cannabinoid pharmaceutical tablet intended to support non-opioid pain management, sleep support, recovery, and quality-of-life improvement. The company seeks U.S.-based GMP-compliant manufacturing partners capable of formulation development, clinical manufacturing, scale-up, regulatory support, and commercial production. Special interest exists in supporting military readiness initiatives, veteran healthcare programs, opioid reduction efforts, and future federal contracting opportunities. Manufacturers with experience supporting government, Department of Defense, VA, and clinical research programs are encouraged to respond.
---	---